Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors

European Journal of Clinical Investigation

Volumn 42, Issue 1, 2012, Pages 42-48

  Fabian, Elisabeth ^a   Bogner, Michaela ^a   Elmadfa, Ibrahim ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular risk factors; Elderly; Enzymatic antioxidants; Oxidative stress

Indexed keywords

ALKADIENE; ANTIOXIDANT; APOLIPOPROTEIN A; CATALASE; DIMETHYLARGININASE; FETUIN A; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

AGE; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PHOTOMETRY; PLASMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AGING; APOLIPOPROTEINS A; ARGININE; CARDIOVASCULAR DISEASES; CATALASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUINS; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RISK FACTORS; STATISTICS AS TOPIC; SUPEROXIDE DISMUTASE;

EID: 83155175361     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02554.x     Document Type: Article

References (46)

1. World Health Organization. Cardiovascular Diseases. Geneva: WHO; 2007.
2. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003;91:12-6.
3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007.
4. Leopold JA, Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med 2009;47:1673-706.
5. Navab M, Hama SY, Reddy ST, Ng CJ, Van Lenten BJ, Laks H et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002;13:363-72.
6. Banos-Gonzalez MA, Pena-Duque MA, Angles-Cano E, Martinez-Rios MA, Bahena A, Valente-Acosta B et al. Apo(a) phenotyping and long-term prognosis for coronary artery disease. Clin Biochem 2010;43:640-4.
7. Böger RH, Bode-Böger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 2000;26:539-45.
8. Moe SM, Chen NX. Inflammation and cardiovascular calcification. Blood Purif 2005;23:64-71.
9. Lankin VZ, Tikhaze AK, Kapel'ko VI, Shepel'kova GS, Shumaev KB, Panasenko OM et al. Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative stress and carbonyl stress. Biochemistry (Mosc) 2007;72:1081-90.
10. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
11. Mehta JL, Li DY. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 1998;248:511-4.
12. Ananyeva NM, Tjurmin AV, Berliner JA, Chisolm GM, Liau G, Winkles JA et al. Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscler Thromb Vasc Biol 1997;17:445-53.
13. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis Markers 2008;24:341-9.
14. El-Melegy NT, Mohamed NA, Sayed MM. Oxidative modification of low-density lipoprotein in relation to dyslipidemia and oxidant status in children with steroid sensitive nephrotic syndrome. Pediatr Res 2008;63:404-9.
15. Ehara S, Ueda M, Naruko T, Haze K, Matsuo T, Ogami M et al. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery disease. J Diabetes Complications 2002;16:60-4.
16. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population. Evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992;89:1040-6.
17. De la Pena-Diaz A, Izaguirre-Avila R, Angles-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000;31:353-9.
18. Marcovina SM, Koschinsky M. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-44.
19. Zlatohlavek L, Zidkova K, Vrablik M, Haas T, Prusikova H, Svobodova H et al. Lipoprotein(a) and its position among other risk factors of atherosclerosis. Physiol Res 2008;57:777-83.
20. Edelstein C, Philips B, Pfaffinger D, Scanu AM. The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulated low-density lipoproteins and are probably of cellular origin. FASEB J 2009;23:950-6.
21. Lamanuzzi LB, Mtairag el M, Pepe G, Angles-Cano E. Neutrophiles stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a). Thromb Haemost 2004;92:1066-75.
22. Zhang WZ, Venardos K, Finch S, Kaye DM. Detrimental effect of oxidized LDL on endothelial arginine metabolism and transportation. Int J Biochem Cell Biol 2008;40:920-8.
23. McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "Arginine Paradox". J Biol Chem 1997;272:31213-6.
24. Butchbach ME, Tian G, Guo H, Lin CL. Association of excitatory amino transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem 2004;279:34388-96.
25. Smart EJ, Ying YS, Conrad PA, Anderson RGW. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol 1994;127:1185-97.
26. Ford ML, Tomilinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant 2010;25:1853-8.
27. Jenkins NT, McKenzie JA, Hagberg JM, Witkowski S. Plasma fetuin-A concentrations in young and older high- and low-active men. Metabolism 2011;60:265-71.
28. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
29. Ramel A, Wagner KH, Elmadfa I. Plasma antioxidants and lipid peroxidation after submaximal resistance exercise in men. Eur J Nutr 2004;43:2-6.
30. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-74.
31. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.
32. Beutler E. Glutathion peroxidase. In: Red Cell Metabolism: A Manual of Biochemical Methods, 3rd edn. New York: Grune and Stratton; 1984: pp 74-6.
33. National Institute of Health and National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
34. Maas R, Böger RH. Old and new cardiovascular risk factors: from unresolved issues to new opportunities. Atheroscler Suppl 2003;4:5-17.
35. Sfar S, Jawed A, Braham H, Amor S, Laporte F, Kerkeni A. Zinc, copper and antioxidant enzyme activities in healthy elderly Tunesian subjects. Exp Gerontol 2009;44:812-7.
36. Ho SP, Chan-Yeung M, Chow KK, Ip MS, Mak JC. Antioxidant enzyme activities in healthy Chinese adults: influence of age, gender and smoking. Respirology 2005;10:305-9.
37. Guo Z, Ran Q, Roberts LJ 2nd, Zhou L, Richardson A, Sharan C et al. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med 2008;44:343-52.
38. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006;533:222-39.
39. Comhair SAA, Thomassen MJ, Erzurum SC. Differential induction of extracellular glutathione peroxidase and nitric oxide synthase 2 in airways of healthy individuals exposed to 100% O(2) or cigarette smoke. Am J Respir Cell Mol Biol 2000;23:350-4.
40. Yamakura F, Matsumoto T, Ikeda K, Taka H, Fujimura T, Murayama K et al. Nitrated and oxidized products of a single tryptophan residue in human Cu, Zn-superoxide dismutase treated with either peroxynitrite-carbon dioxide or myeolperoxidase-hydrogen peroxyde-nitrite. J Biochem 2005;138:57-69.
41. Ghosh S, Janocha AJ, Aronica MA, Swaidani S, Comhair SA, Xu W et al. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J Immunol 2006;176:5587-97.
42. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008;118:75-83.
43. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006;20:559-61.
44. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroad. Proc Natl Acad Sci USA, 2003;100:11201-6.
45. Budoff MJ. Atherosclerosis imaging and calcified plaque: coronary artery disease risk assessment. Prog Cardiovasc Dis 2003;46:135-48.
46. Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial 2007;20:103-9.